Latest Breaking News On - Companies of johnson - Page 1 : vimarsana.com

Johnson & Johnson Expands IP Policy to Create Broad Access in 128 Countries for Development of New and Optimized HIV Medicine Formulations for Children Living with HIV

Mayo woman awarded prestigious bursary for health economics

Mayo woman awarded prestigious medal for Health Economics

The Westport woman received the Janssen Bursary medal at a presentation hosted by Janssen Sciences

Janssen Announces approval of ERLEADA® (apalutamide), the first and only branded novel hormonal therapy with once-daily, single-tablet option now available in Ireland

Janssen, the Pharmaceutical Companies of Johnson & Johnson has announced that an additional tablet strength of ERLEADA® (apalutamide) has been

Johnson & Johnson : Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Lazertinib, in combination with RYBREVANT®▼ (amivantamab), for the First-Line Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer -December 21, 2023 at 08:44 am EST

News Release Media Contacts: Zayn Qureshi +44 7760 334666 Email: zqureshi@its.jnj.com Investor...

DARZALEX® (daratumumab) Subcutaneous Formulation-Based

Understanding The FDA's Current Focus On Risk Evaluation And Mitigation Strategies - Food and Drugs Law

Earlier this year, the FDA asked for comments about how the government handles change requests from drug sponsors with risk evaluation and mitigation strategies (REMS).

New VOYAGER PAD Analyses Reinforce Benefit of XARELTO® (rivaroxaban) Plus Aspirin Across High-Risk and Complex Patient Populations with Peripheral Artery Disease (PAD)

Phase 2 Nipocalimab Data Establish Proof of Mechanism in Adults Living with Moderate to Severe Rheumatoid Arthritis, Supporting its Progression into a Combination Study

Johnson & Johnson : Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor -October 23, 2023 at 07:22 am EDT

News Release Media Contacts: Suzanne Frost +1 416-317-0304 Brian Kenney +1 215-620-0111 ...